Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.41 |
| ▸ | YAP1 | P46937 | 3/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23540305 | 0.94 | GPR119 (0.47) | GPR119YAP1TLR9TLR7PRMT5 | |
| SCHEMBL31129464 | 0.94 | GPR119 (0.36) | GPR119YAP1TLR9TLR7PRMT5 | |
| SCHEMBL23541288 | 0.92 | GPR119 (0.47) | GPR119TLR9TLR7 | |
| SCHEMBL31129661 | 0.91 | YAP1 (0.40) | GPR119YAP1TLR9TLR7PRMT5 | |
| SCHEMBL24125476 | 0.89 | YAP1 (0.35) | GPR119YAP1TLR9TLR7 | |
| SCHEMBL30376834 | 0.89 | YAP1 (0.35) | GPR119YAP1TLR9TLR7 | |
| SCHEMBL24818110 | 0.89 | GPR119 (0.34) | GPR119YAP1TLR9TLR7 | |
| SCHEMBL31397229 | 0.89 | GPR119 (0.34) | GPR119YAP1TLR9TLR7 | |
| SCHEMBL32672133 | 0.89 | YAP1 (0.44) | GPR119YAP1TLR9TLR7PRMT5 | |
| SCHEMBL30273947 | 0.88 | GRM5 (0.37) | GPR119TLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | GPR119 3564/4885YAP1 2995/4885TLR9 4815/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | GPR119 3746/4885YAP1 1329/4885TLR9 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.